Angiotensin-converting enzyme inhibition by quinapril blocks the albuminuric effect of atrial natriuretic peptide in Type 1 diabetes and microalbuminuria

Diabetic Medicine

Volumn 17, Issue 3, 2000, Pages 219-224

  McKenna, K ^a   Smith, D ^b   Barrettt, P ^b   Glenn, A ^a   Kesson, C M ^a   Connell, J ^c   Thompson, Cris J ^b  

^a VICTORIA INFIRMARY   (United Kingdom)

^b BEAUMONT HOSPITAL   (Ireland)

^c WESTERN INFIRMARY   (United Kingdom)

Author keywords

Angiotensin converting enzyme inhibitors; Atrial natriuretic peptide; Diabetes mellitus; Microalbuminuria

Indexed keywords

ALBUMIN; ATRIAL NATRIURETIC FACTOR; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; NEUTRAL INSULIN; PLACEBO; QUINAPRIL;

ADULT; ARTICLE; BLOOD PRESSURE REGULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; ENZYME INHIBITION; HUMAN; HYPERTENSION; INSULIN DEPENDENT DIABETES MELLITUS; MALE; MICROALBUMINURIA; SINGLE BLIND PROCEDURE;

ALBUMINURIA; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ATRIAL NATRIURETIC FACTOR; CREATININE; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN; ISOQUINOLINES; KINETICS; MALE; PLACEBOS; TETRAHYDROISOQUINOLINES;

EID: 0034003449     PISSN: 07423071     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1464-5491.2000.00255.x     Document Type: Article

References (28)

1. 1 Mogensen C. Urinary albumin excretion in early and long-term juvenile diabetes. Scand J Clin Lab Invest 1971; 28: 101-117.
2. 2 Viberti G, Hill R, Jarret R. Microalbuminuria as a predictor of clinical nephropathy in insulin dependent diabetes mellitus. Lancet 1982; 320: 1430-32.
3. 3 Ortola FV, Ballerman BJ, Anderson S, Mendez RE, Brenner BM. Elevated plasma atrial natriuretic peptide levels in diabetic rats. J Clin Invest 1987; 80: 670-674.
4. 4 Ferri C, De Mattia G, Piccoli A, Santucci A, Laurenti O, Balsano F et al. Atrial natriuretic peptide in hypertensive and normotensive diabetic patients. Diabetes Care 1994; 17: 195-200.
5. 5 Sawicki PT, Heinemann L, Rave K, Hohmann A, Berger M. Atrial natriuretic factor in various stages of nephropathy. J Diabetes Complic 1988; 2: 207-209.
6. 6 Fioretto P, Sambataro M, Cipollina MR, Giorato C, Carraro A, Opocher G et al. Atrial natriuretic peptide in the pathogenesis of sodium retention in IDDM with and without glomerular hyperfiltration. Diabetes 1992; 41: 936-945.
7. 7 Bell GM, Bernstein RK, Laragh JH, Atlas SA, James GD, Pecker MS et al. Increased plasma atrial natriuretic factor and reduced plasma renin in patients with poorly controlled diabetes. Clin Sci 1989; 77: 177-182.
8. 8 Jungmann E, Graeber S, Scherberich J, Usadel KH. The role of atrial natriuretic peptide in the pathogenesis of nephropathy in patients with type 1 diabetes mellitus. Med Klinik 1992; 87: 622-625.
9. 9 Firth R, Gafney M, Skelly R, Deegan P, Dowsett D. Is atrial natriuretic peptide associated with glomerular hyperfiltration in diabetics. Diabetologia 1993; 36: A217.
10. 10 Zietse R, Derks FH, Weimar W, Schalekamp MA. Effect of atrial natriuretic peptide on renal and vascular permeability in diabetes mellitus. J Am Soc Nephrol 1995; 5: 2057-2066.
11. 11 Prasad N, Clarkson PBM, MacDonald TM, Ryan M, Struthers AD, Thompson CJ. Atrial natriuretic peptide increases urinary albumin excretion in men with type 1 diabetes mellitus and established microalbuminuria. Diabetic Med 1998; 15: 678-682.
12. 12 McKenna K, Thompson CJ. Atrial natriuretic peptide induces microalbuminuria in insulin dependent diabetic subjects with normal urine albumin excretion rates. Diabetologia 1998; 41: A39.
13. 13 Rudberg S, Aperia A, Freyschuss U, Persson B. Enalapril reduces microalbuminuria in young normotensive type 1 (insulin dependent) diabetic patients irrespective of its hypotensive effect. Diabetologia 1990; 33: 470-482.
14. 14 Lewis EJ, Hunsicker I.G, Bain RP, Rohde RD. The effect of angiotensin converting enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456-1462.
15. 15 Zietse R, Derkx FH, Weimar W, Schalekamp MA. Angiotensin converting enzyme inhibition does not correct early defects in renal and vascular permeability in diabetes mellitus. Clin Sci 1998; 94: 165-173.
16. 16 Heeg JE, de Jong PE, van der Hem GK, de Zeeuw D. Efficacy and variability of the antiproteinuric effect of ACE inhibition by lisinopril. Kidney Int 1989; 36: 272-279.
17. 17 Morton JJ, Webb DJ. Measurement of plasma angiotensin 2. Clin Sci 1985; 68: 483-484.
18. 18 Duggan KA, Hodge G, Makarious MM, Charlesworth JA. Renoprotective differences between perindopril and enalapril in the diabetic hypertensive rat do not reflect glomerular angiotensin converting enzyme activity. Clin Sci 1998; 94: 511-516.
19. 19 Ondetti MA. Structural relationships of angiotensin converting enzyme inhibitors to pharmacologic activity. Circulation 1988; 77: 72-78.
20. 20 Johnston CI. Angiotensin converting enzyme and its inhibition in the heart and blood vessels. J Cardiovascular Pharmacol 1992; 20: 6-11.
21. 21 Kinoshita K, Urata H, Bumpus FM, Hussain A. Measurement of angiotensin 1 converting enzyme inhibition in the heart. Circulation Res 1993; 73: 51-60.
22. 22 Urata H, Nishimura H, Ganten D. Chymase dependent angiotensin II forming systems in humans. Am J Hypertension 1996; 9: 277-284.
23. 23 Anderson S, Jung FF, Ingelfinger JR. Renal renin angiotensin system in diabetes: functional, immunohistochemical and molecular biologic correlations. Am J Physiol 1993; 265: F477-486.
24. 24 Mombouli JV, Vanhoutte PM. Heterogeneity of endothelium dependent vasodilator effects of angiotensin converting enzyme inhibitors. Role of bradykinin generation during ACE inhibition. J Cardiovascular Pharmacol 1992; 20: 74-82.
25. 25 Boric MP, Croxatto HR. Inhibition of atrial natriuretic peptide excretory action by bradykinin. Hypertension 1995; 26 (6 Part 2): 1167-1172.
26. 26 Perich RB, Jackson B, Rogerson F, Mendelsohn FAO, Paxton D, Johnstonc CI. Two binding sites on angiotensin converting enzyme; evidence from radiological binding studies. Mol Pharmacol 1993; 42: 286-293.
27. 27 Fried TA, McCoy RN, Osgood RW, Stein JH. Effects of atriopeptin 11 on determinants of glomerular filtration rate in the in vitro perfused dog glomerulus. Am J Physiology 1986; 250: 1119-1122.
28. 28 Marin-Grez M, Fleming IT, Steinhausen M. Atrial natriuretic peptide causes preglomerular vasodilation and post glomerular vasoconstriction in rat kidney. Nature 1986; 324: 473-476.